# Uncovering the Independent Role of Lipid Peroxidation in Osteoporosis Through an Integrated Bibliometric and Bioinformatics Analysis

**Authors:** Xin Li, Liqi Ng, Wei Dong, Mengen Li, Yingtao Bai, Yusong Liu, Chunbao Wu, Yu Zhou

PMC · DOI: 10.1155/mi/1064232 · Mediators of Inflammation · 2026-02-16

## TL;DR

This study combines bibliometric and bioinformatics methods to explore the role of lipid peroxidation in osteoporosis, identifying key targets for potential therapies.

## Contribution

The first integrated analysis of lipid peroxidation's independent role in osteoporosis, distinct from ferroptosis.

## Key findings

- Lipid peroxidation emerged as a key research frontier in osteoporosis since 2023.
- Five key targets (APP, FOXO1, FOXO3, JUN, SNCA) were identified with good diagnostic efficacy.
- Common OP–LP targets are enriched in pathways like NF-κB and estrogen signaling.

## Abstract

This study, utilising bibliometric analysis combined with bioinformatics approaches, systematically analysed research trends in the fields of osteoporosis (OP) and autophagy (ATG) over the past two decades, with a focus on the emerging frontier of lipid peroxidation (LP). The aim was to reveal its independent role in the OP network, distinct from the ferroptosis framework.

CiteSpace.6.4.R1 was utilised to perform visualisation analysis on 588 relevant articles from the Web of Science Core Collection, examining countries, institutions, authors, and keywords. Common targets between OP and key burst terms were screened via the Gene Expression Omnibus (GEO) database, followed by the construction of a protein–protein interaction (PPI) network and gene ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Subsequently, we constructed 113 models using 12 machine learning algorithms to screen for feature genes, and the diagnostic value of key targets was validated using receiver operating characteristic (ROC) curves.

Bibliometric analysis indicated that the field entered a period of rapid development from 2018, with China dominating in terms of publication volume and the United States leading in academic influence. Keyword burst detection identified ‘LP’ as an emerging frontier since 2023. Bioinformatics analysis identified 127 common OP–LP targets, which are enriched in pathways such as NF‐κB, eestrogen signalling, and mitophagy. Through machine learning and MCODE module analysis, five key targets were ultimately screened: Amyloid beta precursor protein (APP), Forkhead Box O1 (FOXO1), Forkhead Box O3 (FOXO3), Jun Proto‐Oncogene (JUN), and Synuclein Alpha (SNCA). ROC curves demonstrated their good diagnostic efficacy.

This study is the first to integrate bibliometric and bioinformatics methods, revealing the macro‐level trends in OP–ATG research and the molecular mechanisms underlying OP–LP crossover. It successfully identified five key OP–LP targets, providing a new perspective for understanding OP mechanisms and developing targeted therapies.

## Linked entities

- **Genes:** APP (amyloid beta precursor protein) [NCBI Gene 351], FOXO1 (forkhead box O1) [NCBI Gene 2308], FOXO3 (forkhead box O3) [NCBI Gene 2309], JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725], SNCA (synuclein alpha) [NCBI Gene 6622]
- **Diseases:** osteoporosis (MONDO:0005298)

## Full-text entities

- **Genes:** APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Atg5 (autophagy related 5) [NCBI Gene 11793] {aka 2010107M05Rik, 3110067M24Rik, Apg5l, Atg5l, Paddy}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Tnfsf11 (tumor necrosis factor (ligand) superfamily, member 11) [NCBI Gene 21943] {aka Ly109l, ODF, OPGL, RANKL, Trance}, Atg7 (autophagy related 7) [NCBI Gene 74244] {aka 1810013K23Rik, Agp7, Apg7l, Atg7l, Gm21553}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, FOXO1 (forkhead box O1) [NCBI Gene 2308] {aka FKH1, FKHR, FOXO1A}, AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, Tnfrsf11b (tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)) [NCBI Gene 18383] {aka OCIF, Opg, TR1}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, RENBP (renin binding protein) [NCBI Gene 5973] {aka RBP, RNBP}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, FOXO3 (forkhead box O3) [NCBI Gene 2309] {aka AF6q21, FKHRL1, FKHRL1P2, FOXO2, FOXO3A}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}
- **Diseases:** Parkinson's disease (MESH:D010300), mitochondrial dysfunction (MESH:D028361), fractures (MESH:D050723), oestrogen deficiency (MESH:D007153), NUTRITION (MESH:D044342), diabetic complications (MESH:D048909), rheumatoid arthritis (MESH:D001172), degenerative diseases (MESH:D019636), inflammation (MESH:D007249), osteogenic impairment (MESH:D012516), ATG (MESH:C564093), OP (MESH:D010024), ENVIRONMENTAL (MESH:D018876), osteoporotic bone (MESH:D058866), bone and joint diseases (MESH:D001847), cytotoxic (MESH:D064420), TS (MESH:D005879), Alzheimer's disease (MESH:D000544), ATS (MESH:D050030), SYSTEMS (MESH:D015619), carcinogenesis (MESH:D063646), remodelling (MESH:D020257), hypoxic (MESH:D002534), NETs (MESH:C536657), COMPUTER (MESH:C000719218), metabolic bone disease (MESH:D001851), bone fragility (MESH:C536063), bone formation (MESH:D058426), LP (MESH:D011017), dysregulation (MESH:D021081), osteoarthritis (MESH:D010003), immune-metabolic diseases (MESH:D008659)
- **Chemicals:** Teriparatide (MESH:D019379), polyunsaturated fatty acids (MESH:D005231), Denosumab (MESH:D000069448), linoleic acid (MESH:D019787), Vitamin D (MESH:D014807), 4-HNE (-), rapamycin (MESH:D020123), fatty acid (MESH:D005227), acrolein (MESH:D000171), MDA (MESH:D015104), Romosozumab (MESH:C557282), iron (MESH:D007501), Lipid (MESH:D008055), Glutathione (MESH:D005978), ATP (MESH:D000255), phospholipid (MESH:D010743), ROS (MESH:D017382), aldehydes (MESH:D000447), cholesterol (MESH:D002784), Sodium Nitroprusside (MESH:D009599)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12909619/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12909619/full.md

## References

71 references — full list in the complete paper: https://tomesphere.com/paper/PMC12909619/full.md

---
Source: https://tomesphere.com/paper/PMC12909619